In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aetna buys out pharmacy JV

Executive Summary

Aetna will own 100% of Aetna Specialty Pharmacy under a deal expected to close in the first quarter of 2006. The health insurer currently owns 40% of the joint venture with Priority Healthcare, which was recently acquired by the pharmacy benefit manager Express Scripts (1"The Pink Sheet" Aug. 1, 2005, p. 22)...

You may also be interested in...



Express Scripts To Buy Priority; Will Aetna Buy Out Pharmacy Joint Venture?

Aetna will consider exercising its option to buy out Priority Healthcare's stake in their specialty pharmacy joint venture following Express Scripts' planned $1.3 bil. acquisition of Priority

Could Eledon’s Anti-CD40L Change Transplant Medicine?

Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation. 

Turning That Frown Upside Down: Treating Depression With Facial Botox Injections

In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS046481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel